Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/refractory disease.
http://ift.tt/2w2mZQq
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου